Frontiers in Immunology (Jun 2022)

Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature

  • Ze Zhang,
  • Ze Zhang,
  • Ze Zhang,
  • Ze Zhang,
  • Jin Shang,
  • Bingyang Hu,
  • Bingyang Hu,
  • Bingyang Hu,
  • Huizhong Shi,
  • Huizhong Shi,
  • Huizhong Shi,
  • Huizhong Shi,
  • Yinbiao Cao,
  • Yinbiao Cao,
  • Yinbiao Cao,
  • Yinbiao Cao,
  • Junfeng Li,
  • Junfeng Li,
  • Junfeng Li,
  • Junfeng Li,
  • Tianyu Jiao,
  • Tianyu Jiao,
  • Tianyu Jiao,
  • Tianyu Jiao,
  • Wenwen Zhang,
  • Wenwen Zhang,
  • Wenwen Zhang,
  • Shichun Lu,
  • Shichun Lu,
  • Shichun Lu

DOI
https://doi.org/10.3389/fimmu.2022.836576
Journal volume & issue
Vol. 13

Abstract

Read online

Worldwide, hepatocellular carcinoma (HCC) is the most common subtype of liver cancer. However, the survival rate of patients with HCC continues to be poor. The recent literature has revealed that long non-coding RNAs (lncRNAs) and the occurrence of pyroptosis can perform a substantial task in predicting the prognosis of the respective condition along with the response to immunotherapy among HCC patients. Thus, screening and identifying lncRNAs corelated with pyroptosis in HCC patients are critical. In the current study, pyroptosis-related lncRNAs (PR-lncRNAs) have been obtained by co-expression analysis. The Least Absolute Shrinkage and Selection Operator (LASSO) and univariate and multivariate Cox regression assessments have been performed to develop a PR-lncRNA prognostic model. The risk model was analysed using Kaplan–Meier analysis, principal component analysis (PCA), functional enrichment annotation, and a nomogram. The risk model composed of five PR-lncRNAs was identified as an independent prognostic factor. The tumour immune microenvironment (TIME) was assessed using model groupings. Finally, we validated the five PR-lncRNAs in vitro using a quantitative real-time polymerase chain reaction (qRT-PCR).

Keywords